Trump fires U.S. Bureau of Labour Statistics head after weak jobs report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
14 minutes ago
- Globe and Mail
Axon Enterprise (AXON) Vs Palantir Technologies (PLTR): Which is the Better Investment?
Strong Q2 results have led to a further uproar in Axon Enterprise AXON and Palantir Technologies PLTR shares this week, remaining two of the hottest momentum stocks. Axon's stock has now spiked over +40% year to date, with Palantir shares surging more than +130%. More astonishing, AXON is up over +640% in the last three years with PLTR skyrocketing more than 1,700%. Considering their millionaire-maker-like gains, investors are surely wondering which of these hot stocks is the better investment at the moment. Axon Thrives on Increased Public Safety Spending Thanks to increased global defense and public safety spending, Axon easily surpassed its Q2 expectations while posting stellar top and bottom line growth. The innovative manufacturer of weapons for the U.S. and international governments posted Q2 sales of $668.54 million, which soared nearly 33% year over year and comfortably topped estimates of $642.98 billion by 4%. Furthermore, this marked the 14 th consecutive quarter of revenue growth above 25%, with CEO Rick Smith stating Axon is seeing broad demand across the company's portfolio, including for its AI services, drones, cameras, and virtual reality solutions. More impressive, Axon's Q2 earnings came in at $2.12 per share, crushing expectations of $1.54 by 37% and soaring 76% from $1.20 in the prior period. Axon has now exceeded the Zacks EPS Consensus for a remarkable 33 consecutive quarters, with a very impressive average earnings surprise of 25.87% in its last four quarterly reports. Palantir's First Billion-Dollar Quarter Also thriving from increased defense spending, including the securement of a $10 billion contract with the U.S. Army, Palantir achieved its first-ever billion-dollar quarter, topping estimates of $938.33 million. This was a 48% spike from Q2 sales of $678.13 million a year ago, as the software provider saw strong demand for its artificial intelligence platform (AIP) outside of the intelligence communities. Pinpointing increased commercial demand for AIP, Palantir CEO Alex Karp stated that companies are using Palantir's tools not just to optimize operations, but to reshape entire business models. Palantir is also taking advantage of its expansive sales growth, with Q2 EPS of $0.16 rising from $0.09 a share in the comparative quarter and edging expectations of $0.14. Notably, Palantir has now reached of exceeded the Zacks EPS Consensus for 11 consecutive quarters with an average earnings surprise of 13.17% over the last four quarters. Axon & Palantir Raise Their Full-Year Guidance Adding fuel to investor sentiment is that Axon and Palantir have raised their full-year revenue guidance. Optimistically, Axon now forecasts fiscal 2025 revenue at $2.65-$2.73 billion, up from $2.6-$2.7 billion. It's also noteworthy that Axon expects full-year adjusted EBITDA of $665-$685 million, raised from $650-$675 million. Pivoting to Palantir, the company raised its FY25 revenue forecast to $4.142 billion-$4.15 billion, up from previous guidance of $3.89 billion-$3.9 billion. The bump is specifically attributed to full-year commercial revenue guidance increasing to over $1 billion, reflecting at least 85% growth. Additionally, Palantir raised its adjusted income from operations guidance to between $1.912 billion-1.92 billion and increased its adjusted free cash flow guidance to $1.8 billion-$2 billion. Monitoring Axon & Palantir's Valuation While Axon is well ahead in terms of moving further past the probability line than Palantir, the price-to-sales ratio may still be a better indicator of judging the value these hot stocks offer to investors at their current levels, rather than price-to-earnings. That said, Axon is also growing into its lofty valuation more swiftly regarding the P/S ratio after a rebranding to reflect its broader mission in public safety technology. To that point, Axon trades at 25X forward sales, which is far more reasonable than Palantir's 104X. Conclusion & Final Thoughts Although Palantir's ability to benefit from the AI boom makes it the better momentum stock at the moment, Axon appears to be the overall better investment when considering its more justifiable valuation. Axon's profitability also makes it a more sound investment, and earnings estimate revisions (EPS) have remained higher, correlating with AXON sporting a Zacks Rank #1 (Strong Buy). On the other hand, Palantir stock lands a Zacks Rank #3 (Hold), and investors may certainly be looking for better entry points given PLTR doesn't offer much fundamental value after such a monstrous year-to-date rally. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON): Free Stock Analysis Report
CTV News
14 minutes ago
- CTV News
PM, premiers strategize next steps in trade war
Vancouver Watch Prime Minister Mark Carney met with premiers to talk tariffs and the ongoing trade war with the U.S. Here's what happened.
Globe and Mail
32 minutes ago
- Globe and Mail
Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday
Key Points The biotech reported its second-quarter earnings just after market close the previous day. It topped analyst estimates on both the top and bottom lines. These 10 stocks could mint the next wave of millionaires › Just after market close, Adaptive Biotechnologies (NASDAQ: ADPT) took the wraps off its second quarter. The following day, investors reacted to this by bidding the biotech company's stock up by almost 6%. That was far higher than the 0.7% lift of the S&P 500 index that day. MRD for the win The commercial-stage Adaptive booked $58.9 million in revenue for the period, a robust 36% improvement over the same quarter of 2024. Much of this growth was due to the company's efforts fighting minimal residual disease (MRD), a cancer disorder in which a relatively small number of cancer cells remain in the body -- and thus present a threat -- after medical treatment. Adaptive revealed that its MRD business was responsible for 85% of the quarter's revenue. Its take grew 42% year over year. At the bottom of the profit and loss statement, Adaptive recorded a net loss of $25.6 million ($0.17 per share). This was much narrower than the more than $46 million deficit of 2024's Q2. With those numbers, the company scored an easy twin beat on the consensus analyst estimates. Those folks were modeling only $49 million and change for revenue, and a significantly deeper net loss of $0.24 per share. A key revenue stream should flow harder On the back of that encouraging growth in the MRD sphere, Adaptive raised its guidance for both the revenue from that business and cash burn. It now expects that MRD will bring in $190 million to $200 million across the entirety of 2025, up from its previous projection of $180 million to $190 million. It did not proffer any guidance for its other major revenue stream, immune medicine. As for cash burn, over the year, it should be $45 million to $55 million. The preceding forecast called for $50 million to $60 million. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
